Cosciens Biopharma Inc
CSCI
Company Profile
Business description
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
Contact
c/o Norton Rose Fulbright Canada LLP
222 Bay Street, Suite 3000
P.O. Box 53
TorontoONM5K 1E7
CANT: +1 843 900-3223
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
40
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.60 | 17.80 | -0.20% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 24,834.54 | 342.39 | -1.36% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 41,020.91 | 366.21 | 0.90% |
| NZX 50 Index | 12,857.52 | 1.55 | 0.01% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,740.80 | 15.60 | -0.18% |
| SSE Composite Index | 3,582.96 | 32.76 | -0.91% |